ClinicalTrials.gg
RecruitingNCT06069583Updated Nov 16, 2026

Implementation of Support in the Care of Adults Living With Type 1 Diabetes

An interventional study of Support platform in Type 1 Diabetes, Metabolic Disease and Endocrine System Diseases, sponsored by McGill University. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by McGill University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
322
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Diabetes Mellitus, Type 1 by McGill University — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · McGill University.

Planned enrollment
Largest of 18
322 · median 27
Started
2024
with 1 other
No phase
15 of 20
1 open now
Registered
18th of 20
by date

Among the 20 studies in Diabetes Mellitus, Type 1 by McGill University, this one has the largest planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2024, is one of 15 with no phase, and was the 18th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 20 studies in Diabetes Mellitus, Type 1 by McGill University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetes Mellitus, Type 1 by McGill University, or all of them as a file.
02

Study summary

The investigators will conduct a trial to evaluate if an online training and support platform can help adults living with type 1 diabetes (T1D) in their diabetes self-management. Investigators will compare a group that has access to the "Support" platform through their usual medical care to a group that accesses the platform independently. The first group will be recruited through four participating clinics in the province of Quebec (Canada). The second group will be composed of adults living with T1D across Canada. Participants will have access to the platform for 12 months and will be asked to complete online questionnaires at the beginning and after 6 and 12 months, and share their glucose reader data with the research team. A subgroup of participants as well as healthcare professionals from the four clinics will be invited to participate in an individual interview aiming to understand the barriers and facilitators of integration "Support" in clinical care.

Read the detailed description

Type 1 diabetes (T1D) is a chronic condition which requires life-sustaining insulin therapy as well as knowledge, skills and confidence to self-manage. Tailored diabetes self-management education (DSME) should be offered to all people living with diabetes (PWT1D) at diagnosis, but also in a timely manner according to needs. DSME has the potential to improve quality of life and decrease diabetes complications. Despite the positive outcomes of other DSME programs, participation rates of DSME vary greatly perhaps because access remains sub-optimal. Also, healthcare professionals (HCPs) face a challenge to remain aware of the particularities of T1D and stay up-to-date on the rapidly evolving evidence-based knowledge, technologies and therapies available. The investigators propose to examine an online training and peer support platform, called "Support" as a potential alternative for DSME.

The overall purpose of this hybrid effectiveness-implementation study is to investigate if integrating the "Support" platform to routine medical care of adults living with T1D (i.e., diabetes team referring to the "Support" platform during appointments) can improve diabetes self- management, in comparison with navigating the "Support" platform independently of usual care (i.e., the platform not being discussed during appointment) (Effectiveness), and to study the factors affecting its implementation in real-life settings (Implementation).

This study is a mixed-method multi-site, 2 arms, non-randomized, type 1 hybrid effectiveness-implementation trial.

ARM 1: PWT1D participants will have access to Support as part of their regular care (their HCPs will use "Support" in their care). PWT1D participants in ARM 1 are followed in one of the 4 participating clinics either in-person or remotely or hybrid.

ARM 2: PWT1D participants will have access to "Support", independently from their regular care (they may initiate discussion about the platform with their diabetes care team who might register themselves on the platform, but will not prompt to any specific section on the platform and will not receive any training about the platform). PWT1D participants in ARM 2 can be followed in any other clinics in Canada.

Implementation data will be gathered through HCP participants in the participating clinics.

Participants will have to answer online surveys at baseline, 6 months and 12 months. After completing the baseline questionnaire, they will receive an access to the platform. A subgroup of participants as well as participating HCPs will be invited for individual interviews to discuss their experience in using the platform.

03

Conditions studied

  • Type 1 Diabetes
  • Metabolic Disease
  • Endocrine System Diseases
  • Autoimmune Diseases
  • Immune System Diseases

Keywords

  • self-management education
  • Hemaglobin A1c
  • Online education
  • adults
  • type 1 diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of T1D (including LADA - latent diabetes in adults)
  • Have access to Internet
  • Use of an active email address
  • Comprehension of English or French
  • Live in Canada

Exclusion criteria

Exclusion Criteria:

- Unable to use the Support platform

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
322 participants (estimated)

Study arms

  • Experimental
    Support integrated in usual care

    PWT1D participants will have access to Support as part of their regular care (their HCPs will use Support in their care). PWT1D participants in ARM 1 are followed in one of the 4 participating clinics either in-person or remotely or hybrid.

    Behavioral: Support platform

  • Active comparator
    Support through independent access

    PWT1D participants will have access to Support, independently from their regular care (they may initiate discussion about the platform with their diabetes care team who might register themselves on the platform, but will not prompt to any specific section on the platform and will not receive any training about the platform). PWT1D participants in ARM 2 can be followed in any other clinics in Canada.

    Behavioral: Support platform

Interventions

  • BehavioralSupport platform

    The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar. Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D.

06

What researchers measure

Primary outcomes

  1. Self-efficacy for diabetes management

    Diabetes Self-Management Questionnaire-Revised (DSMQ-R; 27-items, score on 10)

    Time frame: 0, 6 and 12 months

Secondary outcomes

  1. Well-being

    WHO-5 well-being index

    Time frame: 0, 6 and 12 months

  2. Continuous Glucose Monitoring (CGM) - % Time in range

    % Time in range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap.

    Time frame: 0, 6 and 12 months

  3. Continuous Glucose Monitoring (CGM) - % Time above range

    % Time above range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap.

    Time frame: 0, 6 and 12 months

  4. Continuous Glucose Monitoring (CGM) - % Time below range

    % Time below range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap.

    Time frame: 0, 6 and 12 months

  5. Continuous Glucose Monitoring (CGM) - Standard deviation

    Standard deviation of the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap.

    Time frame: 0, 6 and 12 months

  6. Continuous Glucose Monitoring (CGM) - % Coefficient of variation

    % Coefficient of variation of the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap.

    Time frame: 0, 6 and 12 months

  7. Hemoglobin A1c

    self-reported last Hemoglobin A1c (date and value) through online questionnaire

    Time frame: 0, 6 and 12 months

  8. Severe hypoglycemic events

    Self-reported severe hypoglycemic events in the past 6 months

    Time frame: 0, 6 and 12 months

  9. Diabetic Ketoacidosis (DKA) events

    Self-reported DKA events in the past 6 months

    Time frame: 0, 6 and 12 months

  10. calls to 911

    Self-reported number of calls to 911 in the past 6 months

    Time frame: 0, 6 and 12 months

  11. calls to 811

    Self-reported number of calls to 811 in the past 6 months

    Time frame: 0, 6 and 12 months

  12. Cost effectiveness (self-efficacy)

    Cost effectiveness of access to Support as part of usual care compared with independent access in terms of incremental cost effectiveness ratio (ICER) for self-efficacy

    Time frame: 6 and 12 months

  13. Cost effectiveness (HbA1c)

    Cost effectiveness of access to Support as part of usual care compared with independent access in terms of incremental cost effectiveness ratio (ICER) for HbA1c

    Time frame: 6 and 12 months

Other outcomes

  1. Implementation question

    Participants will be asked where they heard about the platform.

    Time frame: 0 month

  2. communication with health care team

    Question about type (in-person, phone, video call or email) and frequency of communication with health care team

    Time frame: 0, 6 and 12 months

  3. Engagement with Support platform (T1D patient) - time in minutes on platform

    Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform

    Time frame: 6, 12 months

  4. Engagement with Support platform (T1D patient) - total pages viewed

    Engagement metrics will be extracted using Google analytics - total pages viewed from the platform

    Time frame: 6, 12 months

  5. Engagement with Support platform (T1D patient) - downloaded documents

    Engagement metrics will be extracted using Google analytics - downloaded documents from the platform

    Time frame: 6, 12 months

  6. Engagement with Support platform (T1D patient) - use of calculators

    Engagement metrics will be extracted using Google analytics - use of calculators on the platform

    Time frame: 6, 12 months

  7. Engagement with Support platform (Health Care Provider) - time in minutes on platform

    Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform

    Time frame: 6, 12 months

  8. Engagement with Support platform (Health Care Provider) - content accessed

    Engagement metrics will be extracted using Google analytics - specific content accessed from the platform

    Time frame: 6, 12 months

  9. Engagement with Support platform (Health Care Provider) - total pages viewed

    Engagement metrics will be extracted using Google analytics - total pages viewed from the platform

    Time frame: 6, 12 months

  10. Engagement with Support platform (Health Care Provider) - downloaded documents

    Engagement metrics will be extracted using Google analytics - downloaded documents from the platform

    Time frame: 6, 12 months

  11. Engagement with Support platform (Health Care Provider) - use of calculators

    Engagement metrics will be extracted using Google analytics - use of calculators on the platform

    Time frame: 6, 12 months

  12. Satisfaction with Support-t platform - T1D patient

    Satisfaction will be rated on a scale from 1 to 10. Higher scores indicate greater satisfaction with the platform.

    Time frame: 6, 12 months

  13. Experience with Support platform (Barriers, facilitators, satisfaction, fidelity) - T1D patient

    Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology

    Time frame: 12 months

  14. Experience with Support platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider

    Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology

    Time frame: 12 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Xie LF, Roy-Fleming A, Haag S, Costa DD, Brazeau AS. Development of the Support self-guided, web application for adults living with type 1 diabetes in Canada by a multi-disciplinary team using a people-oriented approach based on the Behaviour Change Wheel. Digit Health. 2023 Jan 24;9:20552076231152760. doi: 10.1177/20552076231152760. eCollection 2023 Jan-Dec. PubMed 36762025 ↗
  • Xie LF, Itzkovitz A, Roy-Fleming A, Da Costa D, Brazeau AS. Understanding Self-Guided Web-Based Educational Interventions for Patients With Chronic Health Conditions: Systematic Review of Intervention Features and Adherence. J Med Internet Res. 2020 Aug 13;22(8):e18355. doi: 10.2196/18355. PubMed 32788152 ↗
  • Kruger J, Brennan A, Thokala P, Basarir H, Jacques R, Elliott J, Heller S, Speight J. The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model. Diabet Med. 2013 Oct;30(10):1236-44. doi: 10.1111/dme.12270. Epub 2013 Aug 19. PubMed 23815547 ↗
  • Stanton-Fay SH, Hamilton K, Chadwick PM, Lorencatto F, Gianfrancesco C, de Zoysa N, Coates E, Cooke D, McBain H, Heller SR, Michie S; DAFNEplus study group. The DAFNEplus programme for sustained type 1 diabetes self management: Intervention development using the Behaviour Change Wheel. Diabet Med. 2021 May;38(5):e14548. doi: 10.1111/dme.14548. Epub 2021 Mar 10. PubMed 33617669 ↗
  • Pereira K, Phillips B, Johnson C, Vorderstrasse A. Internet delivered diabetes self-management education: a review. Diabetes Technol Ther. 2015 Jan;17(1):55-63. doi: 10.1089/dia.2014.0155. PubMed 25238257 ↗
  • Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. PubMed 22310560 ↗
  • Schmitt A, Kulzer B, Ehrmann D, Haak T, Hermanns N. A Self-Report Measure of Diabetes Self-Management for Type 1 and Type 2 Diabetes: The Diabetes Self-Management Questionnaire-Revised (DSMQ-R) - Clinimetric Evidence From Five Studies. Front Clin Diabetes Healthc. 2022 Jan 13;2:823046. doi: 10.3389/fcdhc.2021.823046. eCollection 2021. PubMed 36994332 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Nov 2027, 42 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 42 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion May 2027 → Nov 2027 and completion Oct 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Oct 6, 2023
StartActual
May 5, 2024
Primary completionEst.
Nov 30, 2027was May 2027
CompletionEst.
May 2028was Oct 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 5, 2027→Nov 30, 2027
Nov 16, 2026
Study completion
Oct 2027→May 2028
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion May 5, 2027→Nov 30, 2027
    Study completion Oct 2027→May 2028
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06069583
Lead sponsor
McGill University
Collaborators
Institut de Recherches Cliniques de Montreal, Centre de Recheche du Centre Hospitalier Université Laval, Centre hospitalier de l'Université de Montréal (CHUM), Centre de médecine métabolique de Lanaudière
Responsible party
Anne-Sophie Brazeau (Associate Professor, McGill University) — Principal investigator
First posted
Oct 6, 2023
Start date
May 5, 2024
Primary completion
Nov 30, 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Anne-Sophie Brazeau, PhD
Contact
anne-sophie.brazeau@mcgill.ca
5143987848
amelie Roy-Fleming, MSc
Contact
amelie.roy-fleming@mcgill.ca
5147790749
Anne-Sophie Brazeau, PhD
principal investigator · School of human nutrition - McGill University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion